Industry articles

ABSORB III: Everolimus Eluting Bioresorbable Scaffolds for Coronary Artery Disease

ABSORB III: Everolimus Eluting Bioresorbable Scaffolds for Coronary Artery Disease

Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had

PCI vs. CABG in

Original title: Comparison of 30-Day and 5-Year Outcomes of Percutaneous Coronary Intervention Versus Coronary Bypass Grafting in Patients Aged ≤50 Years.  Reference: Fausto Biancari, et al. Am J Cardiology Article in Press. Coronary artery bypass grafting (CABG) is associated with better evolution than percutaneous coronary intervention (PCI), mainly due to left main and multiple vessels re interventions.

Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel

Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high


Original title: Trans-Radial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen’s test Results. Reference: Marco Valgimigli et al. J Am Coll Cardiol. 2014. Epub ahead of print. Radial access is associated with a chance of occlusion of the vessel in between 0.8 % and 30 % according to different series. Given this fact, the Allen test

Validation of the Bleeding Academic Research Consortium

Reference: Circulation. 2012; 125:1424–143 Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or,

Angioplasty with stenting in ischemic stroke when thrombolytic agents won

Original title: A Controlled Trial of Revascularization in Acute Stroke. Reference: Martin Roubec et al. Radiology. 2012;Epub ahead of print. One of the most crucial forecast factors in patients undergoing acute ischemic stroke, stroke caused by a blockage in a brain artery, is the time window to recanalization.  Thrombolytic agents have been proved useful but not always achieve

2nd-generation drug-eluting stents, results for

Original title: Clinical Outcome Following Stringent Discontinuation of Dual Anti-Platelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: Two-Year Follow-up of the Randomized TWENTE Trial. Reference: Keneth T, Hanim S, et al. J Am Coll Cardiol 2013. Article in press. In recent years there have been new drug-eluting stents

TOTAL Trial: The Best on Manual Thrombectomy in AMI Patients

Original title: Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. Reference: S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe

ABSORB EXTEND trial: preliminary report of clinical outcomes at 12 months in the first 512 patients

Original title: The ABSORB EXTEND Study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. Reference: Alexandre Abizaid et al.  EuroIntervention 2015;10:1396-1401. The safety and efficacy of the Absorb Bioresorbable Vascular Scaffold (Absorb BVS) has been previously shown in 131 patients of the ABSORB trial cohorts A and B.  Following this trial, the prospective

Long Term Outcomes of the Transcatheter Pulmonary Valve Melody

Original title: Clinical and Hemodynamic Outcomes Up to 7 Years After Transcatheter Pulmonary Valve Replacement in the US Melody Valve Investigational Device Exemption Trial. Reference: Circulation. 2015 May 5. [Epub ahead of print]. Published studies on transcatheter pulmonary valve replacement with the Melody valve have shown good short term outcomes but there is no information of long term

DES and programmed surgery: reality or myth

Original title: Drug-Eluting Stents versus Bare Metal Stents Prior to Noncardiac Surgery. Reference: Sripal Bangalore, et al. Catheterization and Cardiovascular Intervention 2015;85:533-41 Drug eluting stents (DES) have proved beneficial compared to bare metal stents (BMS), but the need to program a surgical procedure after a percutaneous coronary intervention (PCI) has limited its use. This study analyzed patients receiving